 
Document Type:  Study Protocol  
Official Title:  A Randomized, Double-Blind, Placebo-Controlled Trial to Compare 
the Duration of Analgesic Efficacy and Safety of Naproxen Sodium 
Tablets and Ibuprofen Tablets in Postsurgical Dental Pain 
Study ID: [REMOVED] 
Document Date:  15-Feb-2018 
 
 Clinical Study Protocol [ZIP_CODE] Page 1 of 55  
Version 3.0 / 15 -Feb-2018  
  
 
Reference Number: BHC- RD-OI-107 
Supplement: Version [ADDRESS_457890] drugs: BAY 117031 / Naproxen Sodium 
Study purpose: Clinical efficacy  
Clinical study phase:  Phase 4 Date:  15-Feb-2018 
Registration:  Not Applicable Version no.: 3.[ADDRESS_457891] Number:  [ZIP_CODE]   
Sponsor:  Bayer HealthCare LLC , Consumer Health  
[ADDRESS_457892] 
[LOCATION_014] [ZIP_CODE], [LOCATION_003]  
Sponsor’s medical expert:    
 
[INVESTIGATOR_366328], Consumer Health  
The study will be conducted in compliance with the protocol, ICH -GCP and any applicable 
regulatory requirements. 
 Confidential  
The information provided in this document is strictly confidential and is intended solely for 
the guidance of the clinical investigation.  Reproduction or disclosure of this 
document - whether in part or in full - to parties not associated with the clinical investigation 
or its use for any other purpose without the prior written consent of the sponsor is not 
permitted.   
Throughout this document, symbols indicating proprietary names ( , TM) may not be displayed.   
Hence, the appearance of product names without these symbols does not imply that these names are not protected.  
 
  
[COMPANY_003]
 Clinical Study Protocol [ZIP_CODE] Page 2 of 55  
Version 3.0 / 15 -Feb-2018  
  
 
Reference Number: BHC- RD-OI-107 
Supplement: Version 5  Signature [CONTACT_8152]’s medically responsible person  
[INVESTIGATOR_240646]. 
Name:    [CONTACT_1221]:    
 
 
 
Date:    Signature:   
 
  
[CONTACT_303161] [ZIP_CODE] Page 3 of 55  
Version 3.0 / 15 -Feb-2018  
  
 
Reference Number: BHC- RD-OI-107 
Supplement: Version 5  Signature [CONTACT_9000]  
[INVESTIGATOR_240646]. 
Name:   
[CONTACT_23682]:  
Date:    Signature:   
[CONTACT_9001][INVESTIGATOR_8912]’s study file and in the respective 
center’s investigator site file.  
In the protocol document, this page may remain unsigned. 
  
[COMPANY_003]
 Clinical Study Protocol [ZIP_CODE] Page 4 of 55  
Version 3.0 / 15 -Feb-2018  
  
 
Reference Number: BHC- RD-OI-107 
Supplement: Version [ADDRESS_457893]  [ZIP_CODE]  
Clinical study phase  4 
Study objective(s)  To compare the duration of analgesic efficacy as determined by [CONTACT_366289] a single oral dose of naproxen sodium 440  mg (2 x 220 mg tablets)  relative to ibuprofen 400 mg (2 x 200 mg tablets) and placebo over [ADDRESS_457894] (SPID 0 -24) of a single dose of naproxen 
sodium 440 mg (2 x 220 mg tablets) relative to ibuprofen 400 mg (2 x 200 mg tablets) and placebo.  
To compare the overall relief from pain (TOTPAR 0 -24) of a single dose of 
naproxen sodium 440 mg (2 x 220 mg tablets) relative to ibuprofen 400 mg (2 x 200 mg tablets) and placebo. 
Test drug(s)  
Name [CONTACT_366329](s)  220 mg  naproxen sodium (x2)  
Route of administration  Oral 
Duration of treatment  Single dose with pain/relief assessments for up to 24 hours  
Reference drug(s)  
 Name [CONTACT_366330](s)  200 mg  ibuprofen  (x2) 
Route of administration  Oral 
Duration of treatment  Single dose with pain/relief assessments for up to 24 hours  
Reference drug(s)  
 Name [CONTACT_366331](s)  Placebo  (x2)  
Route of administration  Oral 
Duration of treatment  Single dose with pain/relief assessments for up to 24 hours  
Background treatment  not applicable  
Indication  pain relief  
  
 Clinical Study Protocol [ZIP_CODE] Page 5 of 55  
Version 3.0 / 15 -Feb-2018  
  
 
Reference Number: BHC- RD-OI-107 
Supplement: Version 5  Diagnosis and main criteria for 
inclusion  /exclusion  
 
 
 
     
  Inclusion Criteria  
• Healthy, ambulatory, male or female volunteers 1 6-40  years of age;  
• Body mass index 18. 5 to 30.0 kg/m2 inclusive;  
• Scheduled to undergo surgical removal of at least [ADDRESS_457895] molars may be removed 
regardless of impaction level.  Supernumerary teeth present may also be removed at the discretion of the oral surgeon;  
• Mandibular molars must demonstrate modified Demi rjian root classification stage, 
D, E, F, G or H ; 
• Have not taken any form of medication or herbal supplements ( i.e., St. Johns  
Wort) within 5 days of admission (except for oral contraceptives, prophylactic antibiotics, or other routine medications to treat benign conditions, such as 
antibiotics to treat acne) and agree not to take any medication (other than that provided to them)  throughout the study;    
• Female subjects of childbearing potential must be using a medically acceptable 
form of birth control for at least 1 month prior to screening (3 months on oral 
contraceptives) [e.g., hormonal contraceptives (oral, patch, injectable or vaginal 
ring), implantable device (implantable rod or intrauterine device), or a double 
barrier], abstinence or in same sex relationship and have a negative pregnancy test 
at Screening and prior to study drug administration.  Female subjects of non -
childbearing potential must be amenorrheic for at least two years or have 
undergone surgical sterilization (i.e. tubal ligation/occlusion, hysterectomy and/or 
bilateral oophorectomy)  
• Have not consumed alcoholic beverages, or foods and beverages containing 
caffeine  (examples; coffee, tea, chocolate, and colas) after midnight prior to 
surgery and agree not to consume any of these foods or beverages throughout  
their stay at study site  
• Use of only short -acting local anesthetic (e.g., mepi[INVESTIGATOR_366274]) 
preoperatively, with a vasoconstrictor and nitrous oxide  at the discretion of the 
Investigator ; 
• Have moderate to severe postoperative pain on the Categorical Pain Intensity 
Scale (a score of at least 2 on a 4 point scale) and a score of ≥ 5 on the 0 -10 pai n 
intensity NRS within 4 .5 hours postsurgery, but no later than 1 4:30 hours +/ - 15 
minutes . 
 
Exclusion Criteria  
• History of hypersensitivity to naproxen sodium, ibuprofen, NSAIDS, aspi[INVESTIGATOR_248], similar pharmacological agents, local anesthetics , rescue medication  or 
components of the investigational products;  
• Evidence or history of clinically significant (in the judgment of the investigator) hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, 
hepatic, psychiatric, neurologic diseases, or malignancies within the last 5 years;  
• Relevant concomitant disease such as asthma (exercise induced asthma is 
permitted); 
• Current or past history of gastrointestinal bleeding or other bleeding disorder(s);  
• Acute illness or active local infection prior to surgery that can interfere with the 
conduct of the study in the judgment of the investigator;  
• Use of any OTC or prescription medications with which the administration of 
naproxen, acetaminophen, ibuprofen or any other NSAIDs, Hydrocodone 
bitartrate and acet aminophen is contraindicated or use of any medications within 5 
days of surgery  until discharge from the study site  (except oral contraceptives, 
prophylactic antibiotics or medications to treat benign conditions such as 
antibiotics to treat acne);  
• Females who areplanning to become pregnant, pregnant or lactating;  
• Habituation to analgesic drugs including opi[INVESTIGATOR_2438] (i.e., routine use of oral 
analgesics [ADDRESS_457896] 2 
years ); 
• Alcoholism or drug abuse within 2 years prior to the Screening Visit or routine consumption of 3 or more alcohol containing beverages per day .  Alcohol 
containing bevera ges are defined as one beer (5%, one glass of wine (11%) and 
one shot hard liquor (40%) ;    
• Positive urine  drug screen , alcohol  breathalyser  or urine cotinine  test on day of 
surgery;                  
• Have received any form of treatment in the form of medication for depression in 
the past 6 months or any form of psychotropic agent (selective serotonin uptake 
inhibitors [SSRI]) within the last 6 months . 
 Clinical Study Protocol [ZIP_CODE] Page 6 of 55  
Version 3.0 / 15 -Feb-2018  
  
 
Reference Number: BHC- RD-OI-107 
Supplement: Version [ADDRESS_457897] who consent and meet all the inclusion and exclusion criteria  will be 
scheduled for surgical removal of impacted teeth under local anesthesia +/ - light 
sedation with nitrous oxide/oxygen.  When subjects  report “moderate” to 
“severe” post -operative pain, they will be dosed with one of the three study 
treatments as determined by a predetermined randomization schedule. Pain 
assessments (Pain Intensity, Pain Relief, Pain Half Gone and Global Assessment ) 
will be performed at scheduled intervals post -drug for 24 hours.  
For each postdose timepoint, pain intensity differences (PID) will be derived by [CONTACT_366290] (baseline score – post-baseline score).  A positive difference is 
indicative of improvement.  Time -weighted sum of pain intensity differences 
(SPI[INVESTIGATOR_29721]) will be calculated by [CONTACT_366291] (in hours) since the preceding timepoint and then 
summing these values over  the desired time interval .  Similarly, total pain relief 
scores (TOTPARs), will be calculated by [CONTACT_366292] (in hours) since the preceding timepoint and  
then summing these values.  
Type of control  Reference product  (positive control) and placebo (negative control)  
Data Monitoring Committee  No 
Number of subjects  385 
Primary variable (s) Time to first use of rescue medication  
Time point/frame of 
measurement for primary 
variable(s)  Pain intensity and pain relief will be rated by [CONTACT_366293] (predose), 0.5, 
1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, 16, 18, 20, 22, and [ADDRESS_457898] stratified by [CONTACT_366294].  
Additional parameters  calculated  for SPID 0 -4, SPID 0 -8, SPID  0-12, SPID  0-24, 
SPID 6 -12, TOTPAR 0 -4, TOTPAR 0 -8, TOTPAR  0-12, TOTPAR  0-24 and 
TOTPAR  6-12 analyzed using an analysis of covariance model (ANCOVA) with 
treatment as fixed effect and baseline pain intensity score as the covariate.   A 
95% of confidence interval (CI) for the treatment difference (naprox en-placebo;  
naproxen -ibuprofen ; ibuprofen -placebo ) will be calculated based on the above 
mentioned model . 
 
 Clinical Study Protocol [ZIP_CODE] Page 7 of 55  
Version 3.0 / 15 -Feb-2018  
  
 
Reference Number: BHC- RD-OI-107 
Supplement: Version [ADDRESS_457899] identification  ............................................................................................. 20  
7. Treatment(s)  ...................................................................................................................... [ADDRESS_457900]- study therapy  ................................................................................................. 26  
9. Procedures and variables  ................................................................................................... 27  
9.1 Tabular schedule of evaluations ............................................................................ 27  
9.2 Visit description  .................................................................................................... 27  
9.2.1  Screening Period  ..................................................................................... 27  
9.2.2  Presurgery  ............................................................................................... 28  
[IP_ADDRESS]  Impaction Score .................................................................... 28  
9.2.3  During Surgery ........................................................................................ 28  
9.2.4  Postsurgery .............................................................................................. 28  
9.2.5  Rescue Medication  .................................................................................. 29  
9.2.6  End of Trial (EOT)  .................................................................................. 30  
9.3 Population characteristics  ...................................................................................... 30  
9.3.1  Demographic ........................................................................................... 30  
9.3.2  Medical history  ........................................................................................ 30  
 Clinical Study Protocol [ZIP_CODE] Page 8 of 55  
Version 3.0 / 15 -Feb-2018  
  
 
Reference Number: BHC- RD-OI-107 
Supplement: Version 5  9.3.3  Other baseline characteristics  .................................................................. 31  
9.4 Efficacy Analysis  .................................................................................................. 31  
9.4.1  Safety Analysis  ........................................................................................ 31  
9.5 Pharmacokinetics / pharmacodynamics  ................................................................ 31  
9.5.1  Pharmacodynamics  ................................................................................. 31  
9.6 Safety  ..................................................................................................................... 32  
9.6.1  Adverse even ts ........................................................................................ 32  
[IP_ADDRESS]  Definitions  ............................................................................ 32  
[IP_ADDRESS]  Classifications for adverse event assessment  ....................... 33  
[IP_ADDRESS].1  Seriousness  ........................................................................... 33 
[IP_ADDRESS].2  Intensity  ................................................................................ 34 
[IP_ADDRESS].3  Causal relationship  ............................................................... 34 
[IP_ADDRESS].4  Action taken with study treatment  ........................................ 35 
[IP_ADDRESS].5  Other specific treatment(s) of adverse events  ....................... 35 
[IP_ADDRESS].6  Outcome  ............................................................................... 36 
[IP_ADDRESS]  Assessments and documentation of adverse events ............. 36  
[IP_ADDRESS]  Reporting of se rious adverse events and pregnancy ............. 36  
[IP_ADDRESS]  Expected adverse events  ....................................................... 37  
9.6.2  Pregnancies  ............................................................................................. 37  
9.6.3  Safety Examinations  ................................................................................ 38  
9.7 Other procedures and variables ............................................................................. 38  
9.8 Appropriateness of procedures / measurements .................................................... 39  
10. Statistical methods and determination of sample size  ....................................................... 40  
10.1  General considerations  .......................................................................................... 40  
10.2  Analysis sets  .......................................................................................................... 40  
10.3  Efficacy Analysis  .................................................................................................. 41  
10.3.1  Primary Efficacy Parameter  .................................................................... 41  
10.3.2  Secondary Efficacy Parameters  ............................................................... 41  
10.3.3  Other Efficacy Parameters  ...................................................................... 41  
10.4  Determination of sample size  ................................................................................ 42  
10.5  Planned interim analyses  ....................................................................................... 42  
11. Data handling and quality assurance  ................................................................................. 43  
11.1  Data recording  ....................................................................................................... 43  
11.2  Monitoring ............................................................................................................. 44  
11.3  Data processing  ..................................................................................................... 44  
11.4  Missing data .......................................................................................................... 44  
11.5  Audit and inspection .............................................................................................. 44  
11.6  Archiving ............................................................................................................... 45  
12. Premature termination of the study  ................................................................................... 46  
13. Ethical and legal aspects  ................................................................................................... 47  
13.1  Investigator(s) and other study personnel ............................................................. 47  
13.2  Funding and financial disclosure ........................................................................... 47  
 Clinical Study Protocol [ZIP_CODE] Page 9 of 55  
Version 3.0 / 15 -Feb-2018  
  
 
Reference Number: BHC- RD-OI-107 
Supplement: Version [ADDRESS_457901] information and consent/assent ................................................................ 48  
13.5  Publication policy and use of data ......................................................................... 49  
13.6  Compensation for health damage of subjects / insurance ..................................... [ADDRESS_457902]  ..................................................................................................................... 51  
15. Protocol amendments ........................................................................................................ 52  
16. Appendices ........................................................................................................................ 53  
16.1  Study Flo w Chart  ................................................................................................... 53  
16.2  Subjective Assessments  ......................................................................................... 54  
 
Table  1: Treatments administered  ............................................................................................ 21  
Table 2: Study treatments  ......................................................................................................... 22  
Table 3: Study schema  ............................................................................................................. 53  
 Figure 1 – Design Overview  .................................................................................................... 16
 
 Clinical Study Protocol [ZIP_CODE] Page 10 of 55  
Version 3.0 / 15 -Feb-2018  
  
 
Reference Number: BHC- RD-OI-107 
Supplement: Version [ADDRESS_457903] of abbreviations  
 
   
 
      
 
     
 
      
  AE Adverse Event  
ANCOVA  Analysis of Covariance  
CDER  Center for Drug Evaluation and Research  
CDISC  Clinical Data Interchange Standards Consortium  
CI Confidence Interval  
COX  Cyclooxygenase  
CRO  Clinical Research Organization  
CSR  Clinical Study Report  
(e)CRF  (electronic) Case Report Form  
EOT  End of Trial  
FDA  Food and Drug Administration  
GCP  Good Clinical Practice  
GMP  Good Manufacturing Practice  
IB Investigator Brochure  
ICF Informed Consent Form  
ICH International Conference on Harmonization  
IMP Investigational Medicinal Product  
IRB/IEC  Institutional Review Board/Independent Ethics Committee  
ITT Intent -to-Treat  
MedDRA  Medical Dictionary for Regulatory Activities  
NPO  nil per os  
NRS  Numerical Rating Scale  
NSAID  Nonsteroidal Anti -inflammatory Drug  
OTC  Over -the-Counter  
PID Pain Intensity Differences  
PP Per Protocol  
QA Quality Assurance  
RNR  Randomization Number  
SAE  Serious Adverse Event  
SAP Statistical Analysis Plan  
SAS Statistical Analysis Software  
SNR  Screening Number  
SSRI  Selective Serotonin Uptake Inhibitors  
SOC  System Organ Class  
SPID  Summed Pain Intensity Difference  
S[LOCATION_003]R  Serious Unexpected Adverse Reaction  
TEAE  Treatment -Emergent Adverse Event  
TOTPAR  Total Pain Relief  
 Clinical Study Protocol [ZIP_CODE] Page 11 of 55  
Version 3.0 / 15 -Feb-2018  
  
 
Reference Number: BHC- RD-OI-107 
Supplement: Version 5  3. Introduction  
Background 
In addition to the information provided below please also refer to the Package Insert for Aleve 
and Advil or any additional data supplied by [CONTACT_1034]. 
 Naproxen sodium  and ibuprofen are nonselective cyclooxygenase (COX) inhibitor s. They are 
propi[INVESTIGATOR_366275] a drug class s known as nonsteroidal anti -
inflammatory drugs (NSAIDs).  Both n aproxen  and ibuprofen inhibit COX -1 and COX -2 
isoenzymes .  COX enzymes play a key role in the inflammatory response and the production 
of prostaglandins.  Specifically, COX -1 is expressed in the gastrointestinal epi[INVESTIGATOR_2130], 
vascular endothelium and kidney, while COX -2 plays a role in induction of inflammation. 
COX-2 inhibition reduces prostaglandin synthesis, leading to pain relief.   In the [LOCATION_002], naproxen has been marketed as a prescription medication since 1976 
under the brand name [CONTACT_366332]
®.  Its sodium salt, naproxen sodium, was first sold under the 
trade name [CONTACT_366333]® in 1980.  In 1994, the US FDA approved naproxen sodium tablets 
(usin g the brand name [CONTACT_366334]®), 220 mg for over -the- counter (OTC) use. Aleve is indicated 
for the temporary relief of minor aches and pains due to: minor pain of arthritis, muscular aches, backaches, menstrual cramps, headaches, toothaches, and the common cold.  It also 
temporarily reduces fever.  As an OTC medication, Aleve should not be taken for longer than 10 days for pain or 3 days for fever unless othe rwise directed by a physician.   Similarly, 
Advil
® (a branded form of ibuprofen) has been available OTC sinc e 1984.  It carries the same 
indications and duration of use labeling  as Aleve.  
 The lab elled dosing interval for over -the- counter naproxen sodium is 8- 12 hours due to its 
long elimination half-life (approxi mately 14 hours) and documented long duration of 
action .[1,2] In contrast, ibuprofen, another propi[INVESTIGATOR_366276]- inflammatory dr ug 
available over -the- counter, has a  labeled dosing interval of 4- 6 hours and a short elimination 
half-life, 2-4 hours.[ 2]  These two agents have been compared in single dose dental pain 
studies.[ 3,4] The analgesic effectiveness of naproxen sodium was greater than ibuprofen at 
later time points in both of these [ADDRESS_457904] been limited by [CONTACT_366295] -home diaries.    
 The duration of analgesia in acute pain studies is  generally assessed by [CONTACT_366296] .[5] At both low OTC doses and high OTC doses, naproxen sodium showed a 
numerically longer duration of action compared to ibuprofen although the difference did not achieve the level of statistical significance. [3,4]  However, the sample size in these two 
studies was not estimated based on thi s secondary outcome parameter.  
 The post- impaction dental pain model chosen for this study  has been widely used in the 
evaluation of OTC and prescription analgesics for a number of reasons. Dental surgical 
procedures can be easily standardized , and the population of subjects undergoing a given 
procedure is usual ly relatively healthy and homogeneous. In addition, there is extensive data 
substantiating the usefulness of the dental pain model in predicting the relative efficacy of a 
wide range of  analgesic medications. The model has been found to be very useful for 
comparing  several measures of analgesic efficacy, including onset, peak effect, and duration 
 Clinical Study Protocol [ZIP_CODE] Page 12 of 55  
Version 3.0 / 15 -Feb-2018  
  
 
Reference Number: BHC- RD-OI-107 
Supplement: Version 5  of analgesic activity . [6,7,8] Therefore, the purpose of this investigation is to use the post-
impaction dental pain model to compare the duration of act ion of naproxen sodium to 
ibuprofen at over-the-counter doses. 
 Clinical Study Protocol [ZIP_CODE] Page 13 of 55  
Version 3.0 / 15 -Feb-2018  
  
 
Reference Number: BHC- RD-OI-107 
Supplement: Version [ADDRESS_457905]-
operative pain relief.   Potential study medication benefit will be relief of postsurgical pain 
which is highly prevalent  following extractions of wisdom teeth.  Potential risks of a single 
dose of OTC study medication are low and described in the Drug Facts Label.  During the study, subjects will be closely monitored for evidence of adverse events.  
Weighing between the potential risks associated with the  study, and given the ability to 
mitigate risks through close monitoring  and routine peri -operative care, this study is 
considered clinic ally and ethically acceptable.
 
  
 Clinical Study Protocol [ZIP_CODE] Page 14 of 55  
Version 3.0 / 15 -Feb-2018  
  
 
Reference Number: BHC- RD-OI-107 
Supplement: Version 5  4. Study obje ctives  
The primary objective of this trial is:  
• To compare the duration of analgesic efficacy as determined by [CONTACT_366297] a single oral dose of naproxen sodium 440  mg (2 x 220 
mg tablets)  relative to ibuprofen 400 mg (2 x 200 mg tabl ets) and placebo (2 x 
tablets) over [ADDRESS_457906]-
impaction surgery dental pain. 
 
The secondary objectives of this trial are:  
• To compare  the overall analgesic effect (SPID  0-24) of a single dose of 
naproxen sodium 440  mg (2 x 220 mg tablets)  relative to ibuprofen 400 mg (2 
x 200 mg tablets) and placebo; 
• To compare  the overall relief from starting pain (TOTPAR  0-24) of a single 
dose of naproxen sodium 440  mg (2 x 220 mg tablets)  relative to ibuprofen 
400 mg (2 x 200 mg tablets) and placebo. 
Other  objectives of this trial are:  
• To compare the efficacy of naproxen 440 mg, ibuprofen 400 mg and placebo for the following measures: 
o SPID 0 -4, SPID 0 -8, SPID 0 -12, SPID 6 -12; 
o TOTPAR 0 -4, TOTPAR  0-8, TOTPAR 0 -12 and  TOTPAR 6 -12; 
o Peak Pain Intensity ; 
o Peak Pain Relief ; 
o Sum of Observations with Pain Half Gone; 
o Duration of Pain Relief At Least Half Gone ; 
o Total amount of time that subject reported at least a 2 -point PID; 
o Global Pain Assessment .  
 Clinical Study Protocol [ZIP_CODE] Page 15 of 55  
Version 3.0 / 15 -Feb-2018  
  
 
Reference Number: BHC- RD-OI-107 
Supplement: Version [ADDRESS_457907]. 
Treatment Phase  
Following selection, qualified subjects will enter the Treatment Phase and be scheduled for 
their surgical teeth  extraction.  After completion of the surgical teeth  extraction s, subjects will 
remain at the study site for observation. Subjects with appropriate pain severity  for 
randomization will then be stratified by [CONTACT_366298] (3) treatment groups.  Subjects will rate th eir pain severity and pain relief over the next 
[ADDRESS_457908] -operative visit /call approximately 6-[ADDRESS_457909]’s participation will be approximately 38 days . For an overview 
on the study design and study procedures see Figure 1.
 
  
 Clinical Study Protocol [ZIP_CODE] Page 16 of 55  
Version 3.0 / 15 -Feb-2018  
  
 
Reference Number: BHC- RD-OI-107 
Supplement: Version 5  Figure 1 – Design Overview   
 
 Screening 
Phase  Treatment Phase  Follow up 
Phase  
Trial 
Days  Day -28 to -1 Day 1  
Presurgery  Day 1  
Surgery  Day 1  
Postsurgery  Day 1  Day 2  Days 6-10 
  Check -in to 
study site          
(if needed)  Surgical 
teeth  
extraction  Categorical 
pain 
NRS pain  NRS pain  
Pain relief  
Pain half 
gone  NRS pain        
Pain relief    
Pain half gone  
Global 
assessment  Phone call 
or visit  
 
 = randomized to either naproxen (440 mg) , ibuprofen (400 mg) , or placebo    
 
Justification of the design  
The study was designed specifically to capture and measure acute post-surgical dental pain in 
healthy subjects who could benefit from the administration of an OTC pain reliever.  This 
pain model has been widely studied for OTC pain medicatio ns; however, should a subject not 
get sufficient pain relief from the IMP, then rescue medication approved for treating acute 
pain (e.g., acetaminophen plus hydrocodone, tramadol, acetaminophen, etc. ) may be 
requested.  The endpoints and study design are co nsistent with most recent Guidance by [CONTACT_366299].[ 9,10] 
          
 
 Clinical Study Protocol [ZIP_CODE] Page 17 of 55  
Version 3.0 / 15 -Feb-2018  
  
 
Reference Number: BHC- RD-OI-107 
Supplement: Version [ADDRESS_457910] extraction of 2 
mandibular partial or full bony impactions.  No more than 25% of the enrolled subjects may be less than 18 years of age. 
6.1 Inclusion criteria 
 
Those who inquire about the trial will be allowed to participate in the study if they  meet the 
following eligibility criteria: 
1. Healthy, ambulatory, male or female volunteers 16 to 40 years of age ; 
2. Body mass index 18.5 to 30.0 kg/m2 inclusive; 
 
3. Scheduled to undergo surgical removal of at least [ADDRESS_457911] molars may be removed regardless of 
impaction level.  Supernumerary teeth present may also be removed  at the discretion of 
the oral surgeon; 
4. Mandibular molars must demonstrate modified Demirjian root classification stage  D, 
E, F,  G or H ; [11] 
5. Have not taken any form of medication or herbal supplements ( i.e., St. Johns Wort) 
within 5 days of admission (except for oral contraceptives, prophylactic antibiotics, 
multivitamin suppleme nts, or other routine medications to treat benign conditions, such 
as antibiotics to treat acne) and agree not to take any medication (other than that provided to them) throughout the study;    
6. Female subjects of childbearing potential must be using a medically acceptable form of birth control for at least 1 month prior to screening (3 months on oral contraceptives) [e.g., hormonal contraceptives ( oral, patch , injectable or vaginal ring), implantable 
device (implantable rod or intrauterine device), or a double barrier ], abstinence or in 
same sex relationship  and have a negative pregnancy test at Screening and prior to 
study drug administration.   Female subjects of non -childbearing potential must be 
amenorrheic for at least two years or have undergone surgica l sterilization (i.e. tubal 
ligation /occlusion, hysterectomy and/or bilateral oophorectomy); 
7. Have not consumed alcoholic beverages, or foods and beverages containing caffeine 
(examples; coffee, tea, chocolate, and colas) after midnight prior to surgery and agree 
not to consume any of these foods or beverages throughout the ir stay at the study site ;    
8. Use of only short- acting local anesthetic (e.g., mepi[INVESTIGATOR_366274]) 
preoperatively, with or without a vasoconstrictor and nitrous oxide at the discretion of the Investigator;  
9. Have moderate to severe postoperative pain on the Categorical Pain Intensity Scale (a score of at least 2 on a 4 point scale) and a score of ≥ 5 on the 0-10 pain intensity NRS within 4.5 hours postsurgery, but no later than 14:30 hours +/- 15 minutes. 
 Clinical Study Protocol [ZIP_CODE] Page 18 of 55  
Version 3.0 / 15 -Feb-2018  
  
 
Reference Number: BHC- RD-OI-107 
Supplement: Version 5  10. Ability to understand and follow study-related instructions; 
11. Be willing and able to participate in all scheduled visits, treatment plan, and  trial 
procedures according to the clinical protocol; 
12.  Subject  must have signed the IRB-approved Informed Consent. 
6.2 Exclusion criteria 
Subjects presenting with any of the following will not be included in the trial: 
1. History of hypersensitivity to naproxen sodium, ibuprofen, NSAIDS, aspi[INVESTIGATOR_248], similar 
pharmacological agents , local anesthetics, rescue medication  or components of the 
investigational products; 
2. Evidence or history of clinically significant (in the judgment of the investigator) 
hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic diseases, or malignancies within the last 5 years ; 
3. Relevant concomitant disease such as asthma (exercise induced asthma is permitted) ; 
 
4. Current or past history of gastrointestinal bleeding or other bleeding disorder(s); 
5. Acute illness or active local infection prior to surgery that can interfere with the 
conduct of the study in the judgment of the investigator; 
6. Use of any OTC or prescription medications with which the administration of 
naproxen, acetaminophen, ibuprofen or any other NSAIDs, Hydrocodone bitartrate and 
acetaminophen ), is contraindicated or use of any medications within 5 days of surgery 
until discharge from the study site (except oral contraceptives, prophylactic antibiotics , 
multivitamin supplements, or medications to treat benign conditions such as antibiotics 
to treat acne) ; 
7. Females who are planning to become pregnant, pregnant or lactating ; 
8. Habituation to analgesic drugs  including opi[INVESTIGATOR_2438]  (i.e., routine use of oral analgesics [ADDRESS_457912] 2 years ); 
9. Alcoholism or drug abuse within 2 years prior to the Screening Visit or routine consumption of 3 or more alcohol containing beverages per day ; Alcohol containing  
beverages are defined as one beer  (5%), one glass of wine (11%) and one shot (40%)  
hard liquor.    
10. Positive urine  drug screen , alcohol breathylyzer or urine cotinine test on day of 
surgery
.    
11. Use of Nicotine containing products within 3 days prior to presurgery  to the 
completion of the study. 
 Clinical Study Protocol [ZIP_CODE] Page 19 of 55  
Version 3.0 / 15 -Feb-2018  
  
 
Reference Number: BHC- RD-OI-107 
Supplement: Version [ADDRESS_457913] 6 months or any form of psychotropic agent (including selective serotonin uptake 
inhibitors [SSRI]) within the last [ADDRESS_457914] -degree relative of study staff or the Sponsor directly involved in the 
study;  
14. Unwilling or unable to comply with all requirements outlined in the protocol; 
15. Subjects with a medical disorder, condition, or history of such that could impair the 
subject’s ability to participate or complete this trial in the opi[INVESTIGATOR_871]; 
16. Previous enrollment in  this study.  
6.3  Justification of selection criteria 
The selection criteria are chosen to ensure that subjects with specific risks for administration of either  study medication and/or subjects with conditions which may have an impact on the 
outcomes of the study are excluded.  
6.[ADDRESS_457915]  be withdrawn from the study if any of the following occurs : 
• At their own request or at the request of their legally acceptable representative. At any 
time during the study and without giving reasons, a subject may decline to participate 
further.  The subj ect will not suffer any disadvantage as a result.  
• Subject’s pain intensity post -surgery at pre -dose does not exceed ‘mild’ and the NRS 
is <5 (see Section 16.2);  
• If, in the Investigator's opi[INVESTIGATOR_1649], continuation of the study would be harmful to the 
subject's well -being;  
•  
Subjects may be withdrawn from the study if any of the following occurs: 
• Subject experiences one or more s erious adverse events; 
• At the  specific request of the Sponsor and in consultation  with the Investigator (e.g. , 
obvious non- compliance, safety concerns);  
• Protocol violation: if the subject develops conditions which would have prevented his/her entry into the study according to the inclusion/exclusion criteria, he/she must 
be withdrawn immediately if safety is concerned; in other cases, the investigator will decide whether there is a conflict with the study objectives.  
 Clinical Study Protocol [ZIP_CODE] Page 20 of 55  
Version 3.0 / 15 -Feb-2018  
  
 
Reference Number: BHC- RD-OI-107 
Supplement: Version [ADDRESS_457916] is  referred to as either a 
“screening failure ”, “run- in failure” or “dropout ” as specified below:  
Screening failure  
A subject who, for any reason ( e.g., failure to satisfy the selection criteria), terminates the 
study prior to the start of surgery  is regarded as a “Screening failure”.  
Re-starting the defined set of screening procedures to enable the “screening failure” subject’s 
participation at a later time point is not allowed – with the following exceptions:  
• The subject had successfully passed the screenin g procedures, but could not start 
subsequent surgery/treatment on schedule. 
• Initial screening occurred too early to complete the required washout period after prior 
therapy.  
• The in clusion / exclusion criteria preventing the subject’s initial attempt to participate 
have been changed (via protocol amendment). 
In any case, the investigator has to ensure that the repeated screening procedures do not 
expose the subject to an unjustifiable health risk. S ubjects who  re -screen  will  re-sign the 
informed consent form, even if it was not changed after the subject’s previous screening and will be assigned a new screening number . 
Run-in failure  
A subject who, for any reason terminates the study after surgery and prior to the start of study 
drug administration (e.g., not meeting pain threshold) is regarded as a “Run- in failure”.  
Dropout 
A subject who discontinues study participation prematurely for any reason is defined as a 
“dropout” if the subject has been randomized and administered at least one dose of study drug. 
General procedures  
In all cases, the reason for withdrawal must be recorded in the case report form/electronic 
case report form (CRF/eCRF)  data collection system  and in the subject's medical records.  
The subject may object to the generation and processing of post- withdrawal data as specified 
in Section  13.4. 
Details for the premature termination of the study as a whole (or components thereof) are provided in Section 12 ( Premature termination of the Study ). 
6.4.[ADDRESS_457917] is identified by [CONTACT_3452]’s unique subject identification code. After informed consent procedure every subject is given a screening number (SNR). At the time 
 Clinical Study Protocol [ZIP_CODE] Page 21 of 55  
Version 3.0 / 15 -Feb-2018  
  
 
Reference Number: BHC- RD-OI-107 
Supplement: Version 5  point of randomization, subjects who meet the entry criteria will be sequential ly assigned to a 
four-digit number in sequential  order (randomization number, RNR).  See Section  7.3. 
 
7. Treatment(s) 
The study center will dispense a single -dose of an assigned treatment within 4.5 hours 
postsurgery.  The tablets and placebo will be administered in a 3:3:1 randomization ratio 
(naproxen sodium; ibuprofen; placebo) based on a computer- generated randomization 
schedule and the severity of pain experienced (moderate or severe).  Subjects who characterize their pain severity as mild and have a NRS <5 will not receive treatment and w ill 
be discharged from the study site, if deemed safe by [CONTACT_39595].  
 
7.1 Treatments to be administered 
The treatments to be administered during the study are displayed in  Section  7.2. 
 
Table  1: Treatments administered  
Treatment  (condition ) Dose / route Amount / form  Frequency of 
administration  
Naproxen sodium 440  mg (postsurgery) 220 mg / orally  2 / tablets  single dose  
Ibuprofen 400 mg (postsurgery ) 200 mg / orally  2 / tablets  single dose  
Placebo (postsurgery)  NA / orally  2 / tablets  single dose  
 
  
 Clinical Study Protocol [ZIP_CODE] Page 22 of 55  
Version 3.0 / 15 -Feb-2018  
  
 
Reference Number: BHC- RD-OI-107 
Supplement: Version 5  7.2 Identity of study treatment 
Table 2: Study treatments  
Treatment  Naproxen  Ibuprofen  Placebo  
Dose  two  tablets  two  tablets  two  tablets  
Pharmaceutical Form  tablet tablet tablet 
Strength 220 mg 200 mg not applicable  
Formulation  naproxen sodium  
FD&C blue #2 lake  
hypromellose  
magnesium stearate  
microcrystalline cellulose  
polyethylene glycol  
povidone  
talc 
titanium dioxide  ibuprofen 
acetylated monoglycerides  
colloidal silicon dioxide  
corn starch  
croscarmellose sodium 
methylp araben  
microcrystalline cellulose  
pharmaceutical glaze  
pharmaceutical ink  
povidone  
pregelatinized starch  
 propylparaben  
sodium benzoate  
sodium lauryl sulfate  
stearic acid  
sucrose  
synthetic iron oxide  
titanium dioxide  
white wax  dibasic calcium phosphate 
dihydrate  
magnesium stearate  
microcrystalline cellulose  
Route of 
administration  orally with a full glass of 
water ( i.e. about 8 ounces  
or 240 mL)  orally with a full glass of 
water ( i.e. about 8 ounces  
or 240 mL)  orally with a full glass of 
water ( i.e. about 8 ounces  
or 240 mL)  
Batch Number  see study file  see study file  see study file  
Trade Name  [CONTACT_366335]® 
Bayer                                         
Bitterfeld, [LOCATION_013]  Advil® 
[COMPANY_007]                                
Madison, NJ [LOCATION_003]  
Bayer                       
Morristown, NJ [LOCATION_003]  
All study drugs will be labeled according to the requirements of local law and legislation.  
Label text will be approved according to the sponsor’s agreed procedures, and a copy of the labels will be made available to the study site upon request.  
For all study drugs, a system of numbering in accordance with all requirements of Good Manufacturing Practice ( GMP ) will be used, ensuring that each dose of study drug can be 
traced back to the respective bulk batch of the ingredients.  Lists linking all numbering levels 
will be maintained by [CONTACT_456]’s clinical supplies Quality Assurance ( QA) group.  
A complete record of batch numbers and expi[INVESTIGATOR_366277].  
The source of test and reference products will be documented in the clinical supply file.  
 Clinical Study Protocol [ZIP_CODE] Page 23 of 55  
Version 3.0 / 15 -Feb-2018  
  
 
Reference Number: BHC- RD-OI-107 
Supplement: Version [ADDRESS_457918] treatment period, after completion of the pre- treatment baseline 
procedures/assessments, subjects who meet the entry criteria will be sequentially assigned to a 
unique number in sequential order (randomization number, RNR) according to the 
randomization schedule 3:3:1 (naproxen sodium: ibuprofen: placebo) prepared prior to the 
study.  
Subjects will be number ed according to the following scheme: 
14001XXXX  
Whereas the “Xs” will be replaced with a four digit sequentially assigned number as each 
subject enters the study (e.g. , first subject number will be 140011001).  
The unique subject identifier number will be assigned in numerical order stratified by [CONTACT_25059] 2 or 3 categorical pain level  (moderate or  severe)  prior to dosing (see Section 16.2
).  Subjects 
who designate their baseline pain as moderate  will use the lowest randomization number 
available with subsequent moderate randomizations using the next available lowest number.  Subjects who designate their baseline pain as severe  will use the highest randomization 
number available with subsequent severe randomizations using the next availa ble highest 
randomization number.  Subjects who characterize their pain severity as mild and <[ADDRESS_457919].   
Subjects completing the Screening Visit, if not scheduled for surgery the same day,  will 
return to the trial site within 28 days, and if they continue to meet inclusion/exclusion criteria postsurgery will be randomized to one of three treatment groups: 
• Naproxen sodium tablets (220 mg x 2 tablets ) 
• Ibuprofen tablets (200 mg x 2 tablets ) 
• Placebo  tablets (2 tablets)  
Subjects will be assigned to treatment groups in accordance with the randomization schedule.  The Sponsor or designee will provide a randomization schedule to the study site.    
7.[ADDRESS_457920] will receive a single dose randomized to naproxen (220 mg x 2 tablets), 
ibuprofen (200 mg x 2 tablets) or placebo (2 tablets).  S ubjects receive the study drug with a 
full glass of non-refrigerated, non- carbonated wat er (about 8 ounces or 240 mL). Study drug 
will be administered using dosing cups. Selection and preparation of the proper dose will be 
performed by [CONTACT_366300] 
(see Section  7.5.1).  The Investigator or a designee will supervise the study drug 
administration  in a manner which maintains the masking conditions (blinding of the subject ).   
Subjects must be NPO from midnight prior to surgery until completion of surgery.  Subject will continue fasting, with the exception of clear liquids, until after study drug administration. 
 Clinical Study Protocol [ZIP_CODE] Page 24 of 55  
Version 3.0 / 15 -Feb-2018  
  
 
Reference Number: BHC- RD-OI-107 
Supplement: Version [ADDRESS_457921] and may not reveal 
the study drug’s identity to any members of the blinded study team. 
Sponsor will supply study medication in bulk containers.  Selection of the proper dose for an 
individual subject will be performed by [CONTACT_366301].  The unblinded study team member will withdraw the appropriate 
study medication from the bulk container and transfer it to a dispensing cup.  The unblinded study team member will then bring the  study medication to the treatment room where it will 
be dispensed to the subject by  [CONTACT_366302].  The unblinded study team 
member should have no other responsibilities in the study. 
 
7.5.2 Unblinding  
In the case of a medical emergency, such as serious adverse events (SAE), breaking the blind may become necessary during the trial.  Randomization code-break envelopes must be securely maintained at the tr ial site and with the Sponsor. 
In compliance with applicable regulations, in the event of a serious unexpected adverse event (S[LOCATION_003]R ) related to the blinded treatment, the subject’s treatment code will usually be 
unblinded before reporting to the health authorities, ethic committees and investigators (see Section [IP_ADDRESS]).  
7.5.[ADDRESS_457922]’s medical record.  The investigator must report the blind break in conjunction with a SAE within [ADDRESS_457923] ( IMP) to 
the study site.  The study center will dispense IMP according to the randomization schedule 
and the subject’s categorical pain intensity (moderate or severe)  postsurgery.  IMP will be 
supplied to the study center in multi-dose bottles and dispensed by [CONTACT_366303].  
 Clinical Study Protocol [ZIP_CODE] Page 25 of 55  
Version 3.0 / 15 -Feb-2018  
  
 
Reference Number: BHC- RD-OI-107 
Supplement: Version 5  All study drug s will be stored at the investigational site in accordance with GCP and GMP 
requirements and the instructions given by [CONTACT_303139] (or 
its affiliate/CRO), and will be inaccessible to unauthorized personnel. Special storage conditions and a complete record of batch numbers and expi[INVESTIGATOR_366278]’s study file; the site -relevant elements of this information will be available in the 
investigator site file. On the day of receipt, the responsible site personnel will confirm receipt of study investigational products in writing. The personnel will use the study investigational 
products only within the framework of this clinical study and in accordance with this protocol. Receipt, distribution, return and destruction (if any) of the study drug must be properly documented according to the sponsor’s agreed and specified procedures. 
7.7 Treatment compliance  
The administration of the study medication will be supervised by a n unblinded member of the 
Investigator’s team. This person will perform the oral cavity inspection after study drug 
administration and  document that the subject receives the tr eatment as planned.  
  
 Clinical Study Protocol [ZIP_CODE] Page 26 of 55  
Version 3.0 / 15 -Feb-2018  
  
 
Reference Number: BHC- RD-OI-107 
Supplement: Version 5  8. Non-study therapy  
8.1 Prior and concomitant therapy 
 
The following treatments are prohibited from  screening and during the study:  
• Use of any form of medication or herbal supplements within [ADDRESS_457924], until discharge from the 
study site ; 
• Use of acetaminophen, naproxen, ibuprofen, aspi[INVESTIGATOR_248], or other NSAIDs or any 
other pain reliever (OTC or prescription) within 5 days before surgery; 
• Use of alcoholic beverages, any food or beverages containing caffeine after 
midnight prior to surgery and throughout the evaluation period; 
• No smoking within 3 days prior to  presurgery to the completion of the study. 
All medications (prescription and nonprescription products, vitamin and herbal products) 
taken by [CONTACT_112646] 30 days prior to Screening to End of Trial (EOT) will be 
documented.  The reported medications will be revie wed and evaluated by [CONTACT_9532] [INVESTIGATOR_366279]’s eligibility to participate in the study.  
8.[ADDRESS_457925]-study therapy  
This study is a single dose administration after surgery and there is no additional treatment 
allocated.  Subjects who randomize into the study will be discharged from the study center 
after the final ([ADDRESS_457926] dosing) assessments, regardless of whether rescue medication  had 
been taken or not. 
 
  
 Clinical Study Protocol [ZIP_CODE] Page 27 of 55  
Version 3.0 / 15 -Feb-2018  
  
 
Reference Number: BHC- RD-OI-107 
Supplement: Version 5  9. Procedures and variables 
9.1 Tabular schedule of evaluations 
See flow chart in Section  16.1 
Regarding protocol deviations, the processes and responsibilities defined by [CONTACT_303140]. Respective details (e.g. , identification and classification of protocol deviations) 
are described separately.  
9.2 Visit description 
If not stated otherwise, the measures / actions listed in the following Sections 9.2.1 to  9.2.6 
will be performed by a designated study team member  as designated by [CONTACT_9532]. 
9.2.1 Screening Period 
Note: No screening procedures may be performed unless subjects have been provid ed an 
IRB-approved written  informed consent  which subjects have read, understood, and 
signed.  
 The Screening Peri od will be up to 28 days long.  The following will be determined during 
the Screening Visit: 
• Signed Informed Consent Form ( ICF); 
• Review inclusion and exclusion criteria; 
• Subject demographics; 
• Medical/surgical history including history of drug, alcohol and tobacco use; 
• Medication history of all prescription, OTC products including vitamins or 
dietary/herbal supplements , taken during the past 30 days; 
• Vital signs consisting of sitting blood pressure, respi[INVESTIGATOR_366280] 5 min utes;  
• Physical and oral examination ; 
• Dental x -ray examination  and interpretation; 
• Urine tests for illicit drugs and cotinine; 
• Breath alcohol test ; 
• Urine pregnancy test (if applicable) ; 
• Impaction score. 
Upon satisfying the inclusion/exclusion criteria, eligible subjects will be instructed to 
return to the trial site within 28 days for oral surgery.  Subjects will be instructed to refrain from the use of all medications (prescription, nonprescription, herbal supplements) unless in the opi[INVESTIGATOR_12182], the medication will not interfere with study procedures, data integrity, or compromise the safety of the subjects.  
 Clinical Study Protocol [ZIP_CODE] Page 28 of 55  
Version 3.0 / 15 -Feb-2018  
  
 
Reference Number: BHC- RD-OI-107 
Supplement: Version 5  Subjects will be instructed not to consume alcohol, any food or beverages containing 
caffeine (e.g., coffee, tea, chocolate, and colas) products after midnight prior to 
surgery.  Surgery will be scheduled between 0630 h and 1000 h (+/ - 30 minutes). 
The Principal Investigator [INVESTIGATOR_022]/her designee must review subject’s study records before qualifying the subject for the trial.  
9.2.2 Presurgery  
Subjects are instructed to be nil per os (NPO) from midnight prior to surgery.  If a subject had 
something to eat or drink after midnight, the surgeon must determine if surgery may proceed.  Subjects will arrive at the unit at their assigned time and will have the following activities completed prior to dental surgery: 
• Review changes in the subject’s medical/medication history and 
inclusion/exclusion criteria since previous visit; 
• Urine tests for illicit drugs and cotinine; 
• Breath alcohol test;  
• Vital signs (sitting blood pressure, pulse rate and respi[INVESTIGATOR_366281] 
5 minutes) ; 
• Urine pregnancy test (if applicable) ; 
• Review pain assessment process  and procedures;  
[IP_ADDRESS]  Impaction Score 
An Impaction Score will be used to assess each tooth based on the radiographic appearance and 
the intraoral examination .  Each tooth will be rated from 1 to 4 using the following 
criteria: (1) erupted in tissue (2) soft tissue impaction  (3) partial bony impaction, and (4) full bony 
impaction.  Only subjects whose mandibular impactions are scored  (3) or (4) will be  eligible to 
participate in the study.  
9.2.3 During Surgery 
During surgery, subjects will be administered a short acting local anesthetic (lidocaine  or 
mepi[INVESTIGATOR_366282]) and nitrous oxide ; at the discretion of the 
dentist/oral surgeon.  Topi[INVESTIGATOR_366283].   Long duration local anesthetics like bupi[INVESTIGATOR_366284].   No other perioperative analgesic or anesthetic agents are permitted. Perioperative 
corticosteroids are not permitted.  
9.2.[ADDRESS_457927] ‘ moderate’ 
or ‘severe’ postoperative pain intensity on the Categorical Pain Rating Scale and a score of ≥ [ADDRESS_457928] suture, but no later than 14:30 +/- 15 minutes. 
 Clinical Study Protocol [ZIP_CODE] Page 29 of 55  
Version 3.0 / 15 -Feb-2018  
  
 
Reference Number: BHC- RD-OI-107 
Supplement: Version [ADDRESS_457929] randomization number and investigational 
products will be administered according to a generated randomization schedule (see Section 7.3). 
Subjects who have not met the randomization criteria within 4.[ADDRESS_457930] suture by 
14:30 h +/ - [ADDRESS_457931] themselves home. 
After the baseli ne (pre -dose) pain intensity is determined, pain intensity , pain relief and pain 
half  gone will be rated by [CONTACT_277935] 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, 16, 18, 20, 22, 
and 24 hours (+/ - [ADDRESS_457932] 6 hours; ±10 minutes from hours 7 through 24 ) 
postdose, and immediately prior to the use of the first dose  rescue medication.  If necessary, 
subjects will be awakened [ADDRESS_457933] dose of  rescue medication (if required) ,  
study subjects will be asked to provide a Global A ssessment  of investigational product as a 
pain reliever  after com pletion of the other assessments.  Additionally, subjects will have vital 
signs taken  after surgery then 1 and  24 hours postdose. 
Throughout the treatment period, the subjects will be monitored for the occurrence of adverse 
events.  Symptoms will be assess ed by [CONTACT_366304] a non- leading question such as “How do you feel? ” or “Are you 
experiencing any other effects?”  All reported  or observed AEs will be collected and recorded 
on the case report form.   The information will be based on signs and symptoms reported by 
[CONTACT_366305]. 
If a subject has any clinically significant, trial -related abnormalities at the conclusion of the 
treatment p eriod, the clinical monitor (or designated representative) should be notified and the 
subject should be asked to remain at the trial site until such abnormalities are stabilized  or 
resolve.  If the subject is unable or unwilling to remain at the trial site, the clinical monitor (or 
designated representative) should be notified, and the Investigator should make every effort to arrange follow -up evaluations at appropriate intervals to document the course of the 
abnormalities.  
Subjects will be allowed the use of ice following the use of rescue medication.  Ice will not be 
permitted for subjects prior to randomization until after they have been administered rescure 
medication (if applicable).  If subject has been administered rescue, ice will be given as 
requested by [CONTACT_256856] [ADDRESS_457934].  Rescue medication will be Hydrocodone 5 mg/ Acetaminophen 
325 mg tablets or other appropriate analgesics may be used at the discretion of the 
Investigator .  Subjects will be required to complete pain assessments by [CONTACT_366306] , 
 Clinical Study Protocol [ZIP_CODE] Page 30 of 55  
Version 3.0 / 15 -Feb-2018  
  
 
Reference Number: BHC- RD-OI-107 
Supplement: Version [ADDRESS_457935]  dose of rescue 
medication.  
• Rating of Pain Intensity (NRS);  
• Rating of Pain Relief (Categorical) ; 
• Pain Half Gone 
• Global A ssessment  of investigational product as a pain reliever. 
Subjects will be queried in a nonspecific fash ion for any adverse events.  All observed and  
reported AEs will be collected and recorded on the case report form.  The information recorded will be based on signs and symptoms reported by [CONTACT_366307] r during clinical evaluation.  
9.2.6 End of Trial (EOT) 
After completion of the treatment period  the following additional evaluations will be 
performed:  
• Trial sites will have the option of either contact[CONTACT_366308] 5 to 9 days after 
surgery (by [CONTACT_648])  or scheduling subjects for an office appointment, depending on 
their standard of care policies, to assess the occurrence or persistence of AEs, any medications taken, and for adequate treatment and follow up.   
9.[ADDRESS_457936] assessment prior to screening, some demographic information may be 
collected before obtaining written informed consent: 
• Year of birth (approximate age); 
• Native language;  
• Reported need for third molar surgery. 
Collection of demographic informat ion is subject to all applicable local regulations.  
9.3.2 Medical history 
Medical history findings ( i.e. previous diagnoses, diseases or surgeries) meeting all criteria 
listed below will be collected  as available to the investigator : 
• Started  before signing of the informed consent; 
• Considered relevant for the  subject’s study eligibility . 
Detailed instructions on the differentiation between (i)  medical history and (ii)  adverse events 
can be found in Section [IP_ADDRESS]. 
 Clinical Study Protocol [ZIP_CODE] Page 31 of 55  
Version 3.0 / 15 -Feb-2018  
  
 
Reference Number: BHC- RD-OI-107 
Supplement: Version 5  9.3.3 Other baseline characteristics 
Information on caffeine, smoking, drug and alcoho l consumption will be collected.  Surgical 
data ( tooth number and diagnosis of each extraction, duration of surgery  in minutes  (first 
incision to last suture), identity and amount of all surgical medications, will be collected . 
9.4 Efficacy Analysis 
For each postdose timepoint, P ain Intensity D ifferences (PID) will be derived by [CONTACT_366309] (baseline score – 
post- baseline score).  A positive difference is indicative of improvement.  Time -weighted sum 
of pain intensity differences (SPI[INVESTIGATOR_29721]) will be calculated for 4, 8, 12, 6-12, and 24 hours by 
[CONTACT_366291] (in hours) since the 
preceding timepoint and then summing these values over 4, 8, 12, 6- 12, and 24 hours, 
respectively.  Similarly, total pain relief scores (TOTPARs), will be calculat ed by [CONTACT_366310] (in hours) since the preceding timepoint and then summing these values. 
In all analyses, for subjects who take rescue medication, all pain intensity scores after intake 
of rescue medication will be replaced by [CONTACT_366311]. All pain relief after intake of rescue medication will be replaced by “no relief” (0).  
A complete list of primary, secondary a nd other efficacy parameters can be found in S ection 
10.3. 
9.4.1 Safety Analysis 
Safety measures will be analyzed for all subjects in the safety population.    
Adverse events will be collected throughout the treatment and safety follow-up periods and will be coded using the Medical Dictionary for Regulatory Activities (MedDRA) dictionary.  
Only treatment-emergent AEs will be included, i.e., AEs that begin or worsen after the first dose of the investigational products in the treatment period.  The number and percent of subjects who experience any event, by [CONTACT_1196] (SOC), and by [CONTACT_366312].  Tables will also be produced by [CONTACT_169973]. Seriousness, severity, relationship to investigational product, duration, and outcome will also be listed. 
9.5 Pharmacokinetics / pharmacodynamics 
Not applicable 
 
9.5.1 Pharmacodynamics 
Not applicable 
 Clinical Study Protocol [ZIP_CODE] Page 32 of 55  
Version 3.0 / 15 -Feb-2018  
  
 
Reference Number: BHC- RD-OI-107 
Supplement: Version 5  9.6 Safety   
9.6.1 Adverse events  
[IP_ADDRESS]  Definitions 
Definition of adverse event (AE)  
In a clinical study, an AE is  any untoward medical occurrence (i.e.  any unfavorable and 
unintended sign [including abnormal laboratory findings], symptom or disease) in a subject or 
clinical investigation subject after providing written informed consent for participation in the study.   Therefore, an AE may or may not be temporally or causally associated with the use of 
a medicinal (investigational) product.   
A surgical procedure that was planned prior to the start of the study by [CONTACT_366313] d as an AE (however, the condition for which the surgery is 
required may be an AE).  
In the following differentiation between medical history and AEs, the term “condition” may include abnormal e.g., physical examinati on findings, symptoms, diseases. 
• Conditions that started before signing of informed consent and for which no symptoms or treatment are present until signing of informed consent are recorded as medical 
history (e.g., seasonal al lergy without acute complaints); 
• Conditions that started before signing of informed consent and for which symptoms or 
treatment are present after signing of informed consent, at unchanged intensity , are 
recorded as medical history  (e.g., allergic pollinosis) ; 
• Conditions that started or deteriorated after signing of informed consent will be 
documented as adverse events .  This includes intercurrent illnesses.  
Definition of serious adverse event (SAE)  
An SAE  is classified as any untoward medical occurrence that, at any dose, meets any of the 
following criteria (a  – f): 
a. Results in death  
b. Is life -threatening  
The term ‘life -threatening’ in the definition refers to an event in which the subject 
was at risk of death at the time of the event, it does not refer to an event which hypothetically might have caused death if it were more severe.  
 Clinical Study Protocol [ZIP_CODE] Page 33 of 55  
Version 3.0 / 15 -Feb-2018  
  
 
Reference Number: BHC- RD-OI-107 
Supplement: Version [ADDRESS_457937] one of the following exceptions is met: 
- The admission results in a hospi[INVESTIGATOR_8932] 12 hours 
- The admission is pre-planned  
(e.g., elective or sched uled surgery arranged prior to the start of the study ; 
admission is part of the study procedures as described in Section  9.2) 
- The admission is not associated with an AE  
(e.g., social hospi[INVESTIGATOR_8933]). 
However, it should be noted that invasive treatment during any hospi[INVESTIGATOR_39675] ‘medically important’ and as such may be reportable as an SAE dependent on clinical judgment.  In addition, where local regulatory authorities specifically require a more stringent definition, the local regulation takes precedence.  
d. Results in persistent or significant disability / incapacity  
Disability  means a substantial disruption of a person’s ability to conduct normal life’s 
functions.  
e. Is a congenital anomaly / birth defect  
f. Is another serious or important medical event as judged  by [CONTACT_093]  
[IP_ADDRESS]  Classifications for adverse event assessment 
All AEs will be assessed and documented by [CONTACT_104709].   
[IP_ADDRESS].[ADDRESS_457938] be determined according to the criteria given in 
Section  [IP_ADDRESS]. 
 Clinical Study Protocol [ZIP_CODE] Page 34 of 55  
Version 3.0 / 15 -Feb-2018  
  
 
Reference Number: BHC- RD-OI-107 
Supplement: Version 5  [IP_ADDRESS].2  Intensity 
The intensity of an AE is classified according to the following categories: 
• Mild : Presents with signs and symptoms easily tolerated, does not need treatment, or 
prolonged hospi[INVESTIGATOR_366285]; 
• Moderate:  A type of adverse event that is usually alleviated with additional specific 
therapeutic intervention. The event interferes with usual activities of daily living, causing discomfort but poses no significant or permanent risk of harm to the research participant; 
• Severe: A type of adverse event that requires intensive therapeutic intervention. The event 
interrupts usual activities of daily living, or significantly affects clinical status. The event 
possesses a significant risk of harm to the research participant and hospi[INVESTIGATOR_303130]. 
 
[IP_ADDRESS].[ADDRESS_457939]/ oral 
surgeon, based on all information available at the time  of the completion of the CRF/eCRF  
data collection system . 
The assessment is based on the question whether there was a “reasonable causal relationship” 
to the study treatment in question.  
Possible answers are “yes” or “no”  
An assessment of “no” would include: 
1. The existence of a highly likely  alternative explanation , e.g. , mechanical bleeding at 
surgical site.  
or 
2. Non-plausibility, e.g., the subject is struck by [CONTACT_23634]; cancer developi[INVESTIGATOR_007] a few days after the first drug administration. 
An assessment of “yes” indicates that that the AE is reasonably associated with the use of the 
study treatment.  
Important factors to be considered in assessing the relationship of the AE to study treatment include: 
- The temporal sequence from drug administration:  The event should occur after the drug is given .  The length of time from drug exposure to event should be evaluated in the 
clinical context of the event.  
- Recovery on drug discontinuation (de- challenge), recurrence on drug re-introduction 
(re-challenge):   Subject’s response after de- challenge or re -challenge should be 
considered in view of the usual clinical course of the event in question. 
- Underlying, concomitant, intercurrent diseases:   Each event should be evaluated in the context of the natural history and course of the disease being treated and any other disease the subject may have.  
 Clinical Study Protocol [ZIP_CODE] Page 35 of 55  
Version 3.0 / 15 -Feb-2018  
  
 
Reference Number: BHC- RD-OI-107 
Supplement: Version 5  - Concomitant medication or treatment:  
The other drugs the subject is taking or the treatment the subject receives should be 
examined to determine whether any of them might have caused the event in question. 
- Known response pattern for this class of drug: Clinical/preclinical  
- Exposure to physical and/or mental stresses: The exposure to stress might induce adverse changes in the recipi[INVESTIGATOR_23567] a logical and better explanation for the event 
- The pharmacology and pharm acokinetics of the study treatment:  
The pharmacokinetic properties (absorption, distribution, metabolism and excretion) of the study treatment, coupled with the individual subject’s pharmacodynamics should be considered. 
- The assessment is not possible 
Causal relationship to  protocol- required procedure(s)  
The assessment of a possible causal relationship between the AE and protocol-required procedure(s) is based on the question whether there was a “reasonable causal relationship” to protocol-required procedure(s).  
Possible answers are “yes” or “no”  
[IP_ADDRESS].4  Action taken with study treatment  
Any action on study treatment to resolve the AE is to be documented using the categories listed below.  
The study treatment action should be recorded separately for each study treatment as detailed in the CRF/eCRF  data collection system . 
- Drug withdrawn  
- Drug interrupted  
- Not applicable 
- Unknown 
[IP_ADDRESS].5  Other specific treatment(s) of adverse events 
- None 
- Remedial drug th erapy  
- Other  
 Clinical Study Protocol [ZIP_CODE] Page 36 of 55  
Version 3.0 / 15 -Feb-2018  
  
 
Reference Number: BHC- RD-OI-107 
Supplement: Version 5  [IP_ADDRESS].6  Outcome 
The outcome of the AE is to be documented as follows:  
- Recovered/resolved  
- Recovering/resolving  
- Recovered/resolved with sequelae  
- Not recovered/not resolved 
- Fatal  
- Unknown 
[IP_ADDRESS]  Assessments and documentation of adverse events 
AEs observed, mentioned upon open questioning by a member of the investigator’s team or 
spontaneously reported by [CONTACT_242589]. The observation phase for AEs 
will start with signing the informed consent form and will end in general with the last visit of follow-up. After the end of follow- up there is no requirement to actively collect AEs.  
In case of ongoing AEs after the last follow -up visit – especially when related to treatment 
with the study medication – the respective AE will be follo wed until resolution, if possible. 
The type of information that should be assessed and recorded by [CONTACT_366314]  [IP_ADDRESS]. 
For all SAEs the sponsor has to carry out a separate assessment for expectedness, seriousness and causal relationship to treatment with the study medication.  
The investigator has to record on the respective CRF/eCRF  data collection system all adverse 
events occurring in the period between the signing of the informed consent and the end of the Follow-up Visit, there is no requirement to actively collect AEs including deaths.  The type of 
information that should be assessed and recorded by [CONTACT_366315]  [IP_ADDRESS].   
“Death” should not be recorded as an AE on the AE page.  Instead, “death” is the outcome of underlying AE(s).  
For all serious adverse events (SAEs) the sponsor has to carry out a separate assessment for expectedness, seriousness and causal relationship to study drug. 
[IP_ADDRESS]  Reporting of serious  adverse events and pregnancy  
The definition of serious adve rse events (SAEs) is given in Section  [IP_ADDRESS].  Each SAE must 
be followed up until resolution or stabilization by [CONTACT_23636][INVESTIGATOR_841].  
Investigator’s notification of the sponsor 
All investigators will be thoroughly instructed and trained on all relevant aspects of the 
investigator’s reporting obligations for SAEs.  This information, including all relevant contact [CONTACT_8972], is summarized in the investigator site file.  This information will be updated as needed.   For clarity it might be useful to state that a pregnancy is to be captured as an SAE 
The investigator must report immediately (within 24  hours of the inves tigator’s awareness) a ll 
SAEs occurring during the observation period defined in Section [IP_ADDRESS] to the recipi[INVESTIGATOR_303131] [ZIP_CODE] Page 37 of 55  
Version 3.0 / 15 -Feb-2018  
  
 
Reference Number: BHC- RD-OI-107 
Supplement: Version 5  detailed in the instructions for SAE reporting included in the Investigator File.  For this, an 
AE page in the CRF/eCRF  data collection system  as well as the complementary pa ges 
provided in the Investigator File must be completed for each SAE .   
Pregnancy occurring during a clinical investigation, although not considered a serious adverse 
event, must be reported to Bayer within the same timelines as a serious adverse event on a Pregnancy Monitoring Form.  The outcome of a pregnancy should be followed up carefully and any abnormal outcome of the mother or the child should be reported.  This also applies to pregnancies following the administration of the investigational product to the father prior to sexual intercourse.  Send the completed SAE or pregnancy forms to: 
 or Fax:  (in the [LOCATION_003])  
SAEs occurring after the protocol-defined observation period will be processed by [CONTACT_366316]. 
Notification of the IRB  
Notification of the Institutional Review Board ( IRB) about all relevant events ( e.g., SAEs, 
suspected, unexpected, serious adverse reactions [ S[LOCATION_003]Rs ]) will be performed by [CONTACT_246221]/or by [CONTACT_57131]. 
Notification of the authorities 
The processing and reporting of all relevant events ( e.g., SAEs, S[LOCATION_003]Rs) to the authorities 
will be done by [CONTACT_366317] g to all applicable regulations.  
Sponsor’s notification of the investigational site The sponsor will inform the investigational site about reported relevant events ( e.g., S[LOCATION_003]Rs) 
according to all applicable regulations. 
[IP_ADDRESS]  Expected adverse events 
For this stu dy, the applicable reference document is the most current version of the package 
insert for naproxen and ibuprofen.  If relevant new safety information is identified, the 
information will be integrated into an update of the safety information  and distribut ed to all 
participating sites.  
The expectedness of AEs will be determined by [CONTACT_366318]. 
9.6.[ADDRESS_457940]’s participation is to be terminated immediately if a pregn ancy is supposed  (i.e. 
in case her pregnancy test becomes positive).   
The investigator must report to the sponsor any pregnancy occurring in a female study subject 
during her participation in this study.  The outcome of the pregnancy should be followed up 
carefully, and any outcome of the mother and the child at delivery should be reported. 
For a pregnancy in the partner of a male study subject, all efforts  will be made to obtain 
similar information on course and outcome, subject to the partner’s consent. 
[COMPANY_003]
[COMPANY_003]
 Clinical Study Protocol [ZIP_CODE] Page 38 of 55  
Version 3.0 / 15 -Feb-2018  
  
 
Reference Number: BHC- RD-OI-107 
Supplement: Version 5  For all reports, the forms provided are to be used.  The investigator should submit them  within  
the same timelines as an SAE (see Section  [IP_ADDRESS] .).  Send the completed pregnancy forms to: 
 or Fax:  (in the [LOCATION_003]) 
9.6.3 Safety Examinations 
The following safety examinations will be performed at the time points specified in the study 
flowchart, see Section  16.1. 
• Physical examination 
The physical examination (by [CONTACT_171128], palpation, auscultation) will be performed by [CONTACT_366319] ( e.g., a physician , oral surgeon, nurse practitioner or physician 
assistant)  at the study site covering at least the organs of the head/neck, cardiovascular, and 
respi[INVESTIGATOR_27441]. 
Abnormal physical examination findings are recorded either as medical history or as adverse events (see Section  [IP_ADDRESS]).  
• Body weight and height, BMI  
Body weight will be measured by a member of the investigator’s team under the following conditions: 
− Subject without shoes after having emptied his / her bladder 
− Physician (column) scale, measurement units 0.[ADDRESS_457941]’s height will be measured (without shoes) to calculate the BMI. 
• Blood pressure / heart rate  
Systolic and diastolic blood pressure and heart rate will be measured by a member of the 
investigator’s team under the following conditions: − Systolic blood pressure (after resting for at least 5 min in sitting position)  
− Diastolic blood pressure (after resting  for at least 5 min in sitting position)  
− Heart rate (after resting for at least 5 min in sitting position)  
− Measuring site: cuff to be placed on the right / left upper arm (if possible, the same arm 
will be used for all measurements in one subject); cuff location will be documented 
− Method: oscillometric by [CONTACT_366320]  
• Laboratory examinations 
Urine samples will be collected by a member of the investigator’s team, for time points and 
parameters see Section 16.1 in the appendix. 
 
9.7 Other procedures and variables 
Eligible subjects will undergo an oral examination and a dental x -ray (ra diograph) exam to 
confirm that impacted  third molar teeth are present.  
[COMPANY_003]
[COMPANY_003]
 Clinical Study Protocol [ZIP_CODE] Page 39 of 55  
Version 3.0 / 15 -Feb-2018  
  
 
Reference Number: BHC- RD-OI-107 
Supplement: Version 5  9.8 Appropriateness of procedures / measurements 
All efficacy and safety parameters, as well as the methods to measure them, are standard 
variables / methods in clinical studies and / or clinical practice. They are widely used and generally recognized as reliable, accurate and relevant.  
 
 
 Clinical Study Protocol [ZIP_CODE] Page 40 of 55  
Version 3.0 / 15 -Feb-2018  
  
 
Reference Number: BHC- RD-OI-107 
Supplement: Version 5  10. Statistical methods and determination of sample size  
10.1 General considerations 
Statistical analysis will be performed using statistical analysis software ( SAS) and the version 
used will be specified in the Statistical Analysis Plan (SAP) and placed on file.  The SAP will 
contain a more comprehensive explanation than described below of the methodology used in the statistical analyses.  The SAP will also contain the rules and data handling conventions used to perform the analyses, and the procedure used for accounting for missing data. 
10.[ADDRESS_457942].  Safety 
measures will be analyzed for all subjects  in the safety population. 
 
Intent- To-Treat (ITT)  
All subjects in the Safety Population w ho provide at least one pain assessment  after the first 
dose of the investigational product.  ITT population will be used as the sensitivity analysis for 
the selected parameters.   
 
Per Protocol (PP) Population 
PP population will include all subjects  in ITT who do not have any major protocol violations. 
PP population will be used as the primary analysis for the efficacy parameters.  
 Major protocol deviations will be identified prior to database lock and may include but are not limited to significant violations of inclusion/exclusion criteria, noncompliance of the trial treatment taken, conditions such as vomiting and diarrhea or use of prohibited medications, and not following clinical trial protocol procedures.  Any subject who rescues  or vomits  at or 
prior to 60 minutes after ingesting study med ication  will be  excluded  from the Per Protocol 
analysis . 
 Clinical Study Protocol [ZIP_CODE] Page 41 of 55  
Version 3.0 / 15 -Feb-2018  
  
 
Reference Number: BHC- RD-OI-107 
Supplement: Version 5  10.3 Efficacy Analysis 
For each postdose timepoint, P ain Intensity D ifferences (PID) will be derived by [CONTACT_366321] (baseline score – 
post- baseline score).  A positive difference is indicative of improvement.  Time -weighted 
Sum of P ain Intensity D ifferences (SPI[INVESTIGATOR_29721]) will be calculated for 4, 8, 12, 6-12 and 24 hours 
by [CONTACT_366291] (in hours) since the preceding timepoint and then summing these valu es over 4, 8, 12, 6- 12 and  24 hours, 
respectively.  Similarly, Total Pain Relief Scores (TOTPARs), will be calculated by 
[CONTACT_366322] (in hours) since the preceding timepoint and then summing these values.  
In all analyses, for subjects who take rescue medication, all pain intensity scores after intake of rescue medication will be replaced by [CONTACT_366311]. All pain re lief after intake of rescue medication 
will be replaced by “no relief” (0).  
10.3.1  Primary Efficacy Parameter 
The primary efficacy analyses population will be based on the PP population. 
The primary efficacy parameter is defined as:  
• Time to first use of rescue m edication.  If a subject did not take the rescue medication 
during the treatment period, (s)he will be censored at the time of last assessment. Time 
to first use of rescue medication will be estimated and plotted using Kaplan -Meier 
method and analyzed using log- rank test stratified by [CONTACT_366323] r and baseline pain 
intensity.  
10.3.2  Secondary Efficacy Parameters 
The secondary efficacy variables include:  
• SPID  0-24 and TOTPAR 0 -24 will be analyzed using an analysis of covariance model 
(ANCOVA) with treatment as fixed effe ct and baseline pain intensity score as the 
covariate.  A 95% of confidence interval (CI) for the treatment differences will be calculated based on the above mentioned model. 
10.3.3  Other Efficacy Para meters  
• The SPID  0-4, 0-8, 0- 12, 6-12 will be analyzed using the same methodology as for 
SPID 0 -24. 
• TOTPAR 0-4, 0-8, 0-12, and TOTPAR  6-12 will be analyzed using the same 
methodology as for SPID 0-24. 
• Pain Intensity Difference (PID) and Pain Relief scores at 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 
10, 11, 12, 14, 16, 18, 20, [ADDRESS_457943] curves will be presented.  
• The cumulative proportion taking rescue medication by [CONTACT_366324]- square tests and time -effect curves will be generated.  Frequency tables will 
be generated for the number of times the subject took rescue medication over the 24 
hour period by [CONTACT_1570]. 
 Clinical Study Protocol [ZIP_CODE] Page 42 of 55  
Version 3.0 / 15 -Feb-2018  
  
 
Reference Number: BHC- RD-OI-107 
Supplement: Version 5  • Percent of subjects with Pain Half Gone (Yes / No question) by 24 hours will be 
summar ized  descriptively by [CONTACT_1570] . 
• The proportion of subjects with pain at least one- half gone at each time point  will be 
summarized descriptively and plotted over time by [CONTACT_1570];  
• Duration of time that subjects reported their pain was at least half gone;  
• Total amount of time that subject reported at least a 2 -point PID; 
• Global A ssessment  of the investigational product as a pain reliever.  This variable will 
be analyzed using CMH method with modified ridit score.  The proportion of subjects 
in each surgery will also be presented.  
Safety and Tolerability 
AEs will be collected from screening throughout the Treatment Phase and Follow-up Phase 
and will be coded using the Medical Dictionary for Regulatory Activities. Only treatment-emergent AEs w ill be included, i.e., AEs that begin or worsen after the first dose of the 
investigational medicinal product ( IMP) in the Treatment Phase.  The number and percent of 
subjects who experience any event and the number of events overall, by [CONTACT_1196], 
and by [CONTACT_366325].  Tables will 
also be produced by [CONTACT_303155]. Seriousness, severity, relationship 
to each IMP duration, and outcome will also be listed. 
Quantitative data for blood pressure, heart rate, body weight, body temperature will be 
described by [CONTACT_303156] f or the differences to baseline.  
Frequency tables will be provided for qualitative data. Laboratory data outside the reference range will be listed and highlighted with ‘L’ for low and ‘H’ for high. An additional table with all abnormal values will be presented.  
Listings of individual su bject data (e.g., vital signs) will be provided.  
10.[ADDRESS_457944] to the time to rescue medication .   
 
 
 
A total of 385 subjects will be randomized 
into the study if a drop-out rate of 5% is assumed. 
10.5 Planned interim analyses 
No interim analysis is planned for this study. 
  
CCI
 Clinical Study Protocol [ZIP_CODE] Page 43 of 55  
Version 3.0 / 15 -Feb-2018  
  
 
Reference Number: BHC- RD-OI-107 
Supplement: Version [ADDRESS_457945] data necessary for analysis and reporting will be provided to the 
Sponsor in CDISC (Clinical Data Interchange Standards Consortium) standard s. 
Interface to local laboratory 
Laboratory test results will be received as electronic data files from the local laboratory. They 
will be transferred to the clinical study database at the study site. For easy access and tracking 
by [CONTACT_1188], the results will be additionally provided in printed form. Test results 
originating directly from the site (e.g. , urine drug screen) will be entered into the CRF/eCRF  
data collection system by [CONTACT_16795]. 
Analytical results generated by [CONTACT_12115] / - ies 
The analytical results will be provided as electronic data files using predefined data formats. Where appropriate, these data will be supplemented with data already available from the CRF/eCRF  data collection system (e.g., specifi c time points, demographic data) before being 
evaluated by [CONTACT_303157](s). Data relevant for the clinical study report will be stored in the sponsor’s validated data repository. 
Source documentation  
Entries made in the CRF/eCRF  data collecti on system must be either verifiable against source 
documents, or have been directly entered into the CRF/eCRF  data collection system, in which 
case the entry in the CRF/eCRF  data collection system will be considered as the source data 
(e.g., time points of  blood sampling).  The site has to ensure the availability of all required 
documentation. Data recorded from screening failures  
Data of 'only screened subjects' will be recorded at least as source data, as far as the reason for 
the premature discontinuation is identifiable .  At minimum, the following data should be 
recorded in the screening log : 
• Demographic information (subject number; year of birth  or age, sex);  
• Date of informed consent; 
•   Reason for premature discontinuation; 
•   Date of last  visit.   
For screening failures with an SAE , the following data should be collected in the CRF/eCRF  
data collection system  in addition to the data specified above: 
• All information related to the SAE such as:  
- Concomitant medication  
- Medical history 
- Other information needed for SAE complementary page  
 Clinical Study Protocol [ZIP_CODE] Page 44 of 55  
Version 3.0 / 15 -Feb-2018  
  
 
Reference Number: BHC- RD-OI-107 
Supplement: Version 5  11.2 Monitoring 
In accordance with applicable regulations, GCP, and sponsor’s/CRO’s procedures, monitors 
will contact [CONTACT_116354], study requirements, and their responsibilities to satisfy regulatory, ethical, and sponsor’s 
requirements .  When reviewing data collection procedures, the discussion will also include 
identification and documentation of source data items. 
The sponsor /designee wi ll monitor the site activity to verify that the:  
• Data are authentic, accurate and complete.   
Supporting data may be requested  (example: blood glucose readings to support a 
diagnosis of diabetes); 
• Safety and rights of subjects are being protected ; 
• Study is  conducted in accordance with the currently approved protocol  
(including study treatment being used in accordance with the protocol); 
• Any oth er study agreements, GCP, and all applicable regulatory requirements are met.  
The investigator and the head of the medical institution (where applicable) agrees to allow the 
monitor direct  access to all relevant documents.  
11.3 Data processing 
Data will be collected as described in Section  11.1 .  Clinical data management will be 
performed in accordance with applicable sponsor’s /CRO’s  standards and data cleaning 
procedures.  This is applicable for data recorded on the CRF/eCRF  data collection system as 
well as for data from other sources (e.g. , laboratory ). 
For data coding ( e.g., AEs, medication), internationally recognized and accepted dictionaries 
will be used. 
11.[ADDRESS_457946] be documented.   
11.5 Audit and inspection 
To ensure compliance with GCP and regulatory requirements, a member of the sponsor’s (or a designated CRO’s) quality assurance unit may arrange to conduct an audit to assess the performance of the study at the study site and of the study documents originating there.  The investigator/institution will be informed of the audit outcome.  
In addition, inspections by [CONTACT_366326](s) are possible.  
The investigator should notify the sponsor immediately of any such inspection. 
The investigator/institution agrees  to allow the auditor or inspector direct access to all relevant 
documents and allocate his/her time and the ti me of his/her staff to the auditor/inspector to 
discuss findings and any issues.  Audits and inspections may occur at any time during or after 
completion of the study. 
 Clinical Study Protocol [ZIP_CODE] Page 45 of 55  
Version 3.0 / 15 -Feb-2018  
  
 
Reference Number: BHC- RD-OI-107 
Supplement: Version [ADDRESS_457947] that ensures that they 
are readily available upon authorities’ request.  
Study subject files will be archived according to local regulations and in accordance with the maximum period of time permitted by [CONTACT_3452] .  Where the archiving procedures do not 
meet  the minimum timelines required by [CONTACT_456], alternative arrangements must be made 
to ensure the availability of the source documents for the required period. 
The investigator/institution notifies the sponsor if the archival arrangements change ( e.g., 
relocation or transfer of ownership). The investigator site file is not to be destroyed without the sponsor’s approval. The contract  with the  investigator/institution will contain all regulations relevant for the study 
center.  
 
 
 Clinical Study Protocol [ZIP_CODE] Page 46 of 55  
Version 3.0 / 15 -Feb-2018  
  
 
Reference Number: BHC- RD-OI-107 
Supplement: Version 5  12. Premature termination of the  study  
The sponsor has the right to close this study (or, if applicable, individual segments thereof 
[e.g., treatment arms; dose steps; centers]) at any time, which may be due but not limited to 
the following reasons:  
• If risk -benefit ratio becomes unaccep table owing to, for example, 
- Safety findings from this study ( e.g., SAEs)  
- Results of any interim analysis  
- Results of parallel clinical studies  
- Results of parallel animal studies  
(on e.g. , toxicity, teratogenicity, carcinogen icity or reproduction toxicity);  
• If the study conduct ( e.g., recruitment rate; drop -out rate; data quality; protocol 
compliance) does not suggest a proper completion of the trial within a reasonable time frame.  
The investigator has the right to close his/her center at any time.  
For any of the above closures, the following applies: 
• Closures should occur only after consultation between involved parties.  Final decision 
on the closure must be in writing;  
• All affected institutions ( e.g., IRB(s); competent authority(ies); study center ; head of 
study center ) must be informed as applicable according to local law; 
• All study materials (except documentation that has to remain stored at site) must be returned to the sponsor.  The investigator will retain all other documents until notif ication is given  by [CONTACT_142086]; 
• In the event  of a partial study closure, ongoing subjects, including those in post study 
follow- up, must be taken care of in an ethical manner.  
Details for individual subject's withdrawal can be found in Sec tion 6.4.1. 
 
 
 Clinical Study Protocol [ZIP_CODE] Page 47 of 55  
Version 3.0 / 15 -Feb-2018  
  
 
Reference Number: BHC- RD-OI-107 
Supplement: Version 5  13. Ethical and legal aspects  
13.1 Investigator(s) and other study personnel 
All other study personnel not included in this section are identified in a separate personnel list 
(not part of this clinical study protocol) as appropriate.  This list will be updated as needed; an abbreviated version with personnel relevant for the centers will be available in each center’s investigator site file.  
Whenever the term ‘investigator’ is noted in the protocol text, it may refer to either the 
principal investigator [INVESTIGATOR_8921], or an appropriately qualified, trained and delegated individual of the investigational site.  
The principal investigator [INVESTIGATOR_366286] (e.g ., health authority, ethics committee , sponsor ) 
before subject recruitment may start at the respective center.  Likewise, all amendments to the protocol must be signed by [CONTACT_458] [INVESTIGATOR_246184].  
A complete list of all participating centers and their investigators, as well as all required signature [CONTACT_9002], will be maintained in the sponsor’s study file.  
The global sponsor of this study is identified on the title page of this protocol.  If required by [CONTACT_1769], local co -sponsors will be nominated; they will be identified on the respective 
country- specific signature [CONTACT_1787].  
13.2 Funding and financial disclosure 
Funding  
This study will be funded by [CONTACT_23662]. 
Financial disclosure  
Each investigator (including principal and/or any sub investigators) who is directly involved 
in the treatment or evaluation of research subjects has to provide a financial disclosure 
according to all applicable legal requirements.  All relevant documentation will be filed in the trial master file.  
13.[ADDRESS_457948], evaluation, and documentation of this study, are designed to ensure that the sponsor and investigator abide by [CONTACT_23663] (GCP) g uidelines and the guiding principles detailed in the 
Declaration of Helsinki.  The study will also be  carried out in keepi[INVESTIGATOR_23577](s) and regulation(s).  
Documented approval from appropriate IRBs will be obtained for all participating 
centers/countries before start of the study, according to GCP, local laws, regulations and organizations.  When necessary, an extension, amendment or renewal of the IRB approval must be obtained and also forwarded to the sponsor.  The responsible unit (e.g., IRB, head of 
 Clinical Study Protocol [ZIP_CODE] Page 48 of 55  
Version 3.0 / 15 -Feb-2018  
  
 
Reference Number: BHC- RD-OI-107 
Supplement: Version 5  the study center/medical institution) must supply to the sponsor, upon request, a list of the 
IEC/IRB members involved in the vote and a statement to confirm that the IRB is organized 
and operates according to GCP and applicable laws and regulations. 
Strict adherence to all specifications laid down in this protocol is required for all aspects of 
study conduct; the investigator may not modify or alter the procedures described in this protocol.   
Modifications to the study protocol will not be implemented by [CONTACT_23664].  However, the investigator or the sponsor may implement a deviation from, or a change of, the protocol to eliminate an immediate hazard(s) to the t rial subjects without prior IRB/sponsor approval/favorable opi[INVESTIGATOR_1649].  As soon as 
possible, the implemented deviation or change, the reasons for it and if appropriate the proposed protocol amendment should be submitted to the IRB/ head of medical 
institution/sponsor.  Any deviations from the protocol must be explained and documented by [CONTACT_093].  
Details on discontinuatio n of the entire study or parts thereof can be found in Section 12. 
13.[ADDRESS_457949] information and consent /assent 
All relevant information on the study will be summarized in an integrated subject information 
sheet and informed consent form provided by [CONTACT_246233].  S ample subject 
information and informed consent /assent  form s are provided as a docum ent separate to this 
protocol.  Subjects  [ADDRESS_457950] use an IRB -approved assent form and a Parental/Guardian informed 
consent form.  Informed consent must first be obtained from the child’s parent or legal guardian before assent may be obtained from the child. 
Based on this subject information sheet, the investigator or designee will explain all relevant 
aspects of the study to each subject  prior to his/her entry into the study ( i.e. before any 
examinations and procedur es associated with the selection for the study are performed or any 
study-specific data is recorded on study- specific forms).  
The investigator will also mention that written approval of the IRB has been obtained. 
Each subject will be  informed about the fol lowing aspects of premature withdrawal:  
• Each subject has the right to withdraw from the study at any time without any 
disadvantage and without having to provide reasons for this decision;   
• The subject ’s consent covers EOT  examinations  as specified in the visit description  
described in Section  9.2.6 to be conducted after withdrawal  of consent; 
• The subject’s data that have been collected until the time of withdrawal will be retained 
and statistically analyzed  in accordance with the statistical analysis plan; 
• Subject -specific data on the basis of material obtained before withdrawal may be 
generated after withdrawal (e.g. , image reading, analysis of biological specimen such as 
blood, urine or tissues); these data would also be retained and statistically analyzed in 
accordance with the statistical analysis plan.  The subject has the right to object to the 
generation and processing of this post-withdrawal data.  For this, he/she needs to sign a corresponding declaration of objection; alternatively, the subject’s oral objection may be documented in the subject’s source data. 
 Clinical Study Protocol [ZIP_CODE] Page 49 of 55  
Version 3.0 / 15 -Feb-2018  
  
 
Reference Number: BHC- RD-OI-107 
Supplement: Version [ADDRESS_457951] agrees to sig n the informed consent form and has done so, may he/she 
enter the study.  Additionally, the investigator will personally sign and date the form.  The 
subject will receive a copy of the signed and dated form.  
The signed informed consent statement is to remain in the investigator site file or, if locally 
required, in the subject ’s note/file of the medical institution.  
In the event that informed consent is obtained on the date that baseline study procedures are performed, the study record or subject´s clinical record must clearly show that informed consent was obtained prior to these procedures. 
For minors or adults under legal protection, consent shall be given by [CONTACT_23666](s). 
The consent of a minor or adult under legal protection shall also be reque sted where such a 
person is able to express his/her own will. His/her refusal or the withdrawal of his/her consent may not be disregarded. 
The informed consent form and any other written information provided to subjects will be 
revised whenever important new information becomes available that may be relevant to the subject’s consent, or there is an amendment to the protocol that necessitates a change to the content of the subject information and / or the written informed consent form.  The investigator will inform the subject of changes in a timely manner and will ask the subject to confirm his/her participation in the study by [CONTACT_23667].  Any revised written informed consent form and written i nformation must receive the IRB`s  
approval / favorable opi[INVESTIGATOR_19349]. 
13.[ADDRESS_457952] free to utilize study data derived from his/her 
center  for scientific purposes, must obtain written consent of the sponsor on the intended 
publication manuscript before its submission.  To this end, the investigator must send a draft of the publication manuscript to the sponsor within a time period specified in the contract.  The sponsor will review the manuscript promptly and will discuss its content with the investigator to reach a mutually agreeable final manuscript.   
13.6 Compensation for health damage of subjects / insurance 
The sponsor maintains clinical trial insurance coverage for this study in accordance with the laws and regulations of the country in which the study is performed. 
 Clinical Study Protocol [ZIP_CODE] Page 50 of 55  
Version 3.0 / 15 -Feb-2018  
  
 
Reference Number: BHC- RD-OI-107 
Supplement: Version [ADDRESS_457953] will be kept confidential and, to the extent permitted by [CONTACT_3999]/or regulations, will not be made publicly available.  
Subject names will not be supplied to the sponsor.  Only the subject number s (SNR and RNR)  
will be recorded in the CRF/eCRF  data collection system, and if the subject name [CONTACT_303164] ( e.g., pathologist report), i t must be obliterated before a copy of the 
document is supplied to the sponsor.  Study findings stored on a computer will be stored in accordance with local data protection laws.  As part of the informed consent process, the 
subjects will be informed in wr iting that representatives of the sponsor, IRB, or regulatory 
authorities may inspect their medical records to verify the information collected, and that all personal information made available for inspection will be handled in strictest confidence and in accordance with local data protection laws.  
If the results of the study are published, the subject’s identity will remain confidential.  
The investigator will maintain a list to enable subjects to be identified.  
 
 
 Clinical Study Protocol [ZIP_CODE] Page 51 of 55  
Version 3.0 / 15 -Feb-2018  
  
 
Reference Number: BHC- RD-OI-107 
Supplement: Version [ADDRESS_457954]  
 
1. Grosser  T, Smyth E, FitzGerald GA. Anti -inflammatory, Antipyretic, and Analgesic 
Agents; Pharmacotherapy of Gout. In: Brunton LL, Chabner BA, Knollmann BC. eds. 
Goodman & Gilman's: The Pharmacological Basis of Therapeutics, 12e [LOCATION_001], NY: McGraw-Hill; 2011. http://accesspharmacy.mhmedic al.com/content.aspx?bookid=1613&sectionid=102161
048. Accessed July 16, 2017. 
2. Kiersch TA, Halladay SC, and Hormel PC. A Single-Dose, Double- Blind Comparison 
of Naproxen Sodium, Acetaminophen, and Placebo in Postoperative Dental Pain. Clin Ther  1994;16(3):394-404 
3. Kiersch TA, Halladay SC, and Koschik M. A Double-Blind, Randomized Study of Naproxen Sodium, Ibuprofen, and Placebo in Postoperative Dental Pain. Clin Ther  
1993;15(5):845-54. 
4. Fricke JR, Halladay SC, and Francisco CA. Efficacy and Safety of Naproxen S odium 
and Ibuprofen for Pain Relief After Oral Surgery. Curr Ther Res 1993;54(6):619-27. 
5. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER).  Guidance for Industry Analgesic Indications: Developi[INVESTIGATOR_366287]. February 2014  https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ ucm384691.pdf Accessed July 16, 2017. 
6. Cooper SA and Desjardins PJ. The value of the dental impaction pain model in drug development.  Methods Mol Biol ,  Szallasi A, Ed.   Humana Press  617: 175 – 190, 
2010. 
7. Cooper SA, Beaver WT. A model to evaluate mild analgesics in oral surgery outpatients. Clin Pharmacol Ther  1976;20:241–50. 
8. Kleinert R, Lange C, Steup A, Black P, Goldberg J, Desjardins P.  Single dose analgesic efficacy of tapentadol in postsurgical dental pain: the results of a randomized, double-blind, placebo-controlled study.  Anesth Analg. 2008;107:2048-55. 
9. Cooper SA, Desjardins PJ, Turk DC, et al. Research design considerations for single-
dose analgesic clinical trials in acute pain: IMMPACT recommend ations.  Pain  
2016;157:288-301. 
10. Singla NK, Desjardins PJ, Chang PD.  A comparison of the clinical and experimental characteristics of four acute surgical pain models: dental extraction, bunionectomy, joint replacement, and soft tissue surgery. Pain . 2014;155:441-56. 
11. Jung YH, Cho BH.  Radiographic evaluation of third molar development in 6- to 24-year-olds.  Imaging Science in Dentistry  2014; 44: 185-91. 
 
  
 Clinical Study Protocol [ZIP_CODE] Page 52 of 55  
Version 3.0 / 15 -Feb-2018  
  
 
Reference Number: BHC- RD-OI-107 
Supplement: Version 5  15. Protocol amendments  
 
Amendment 1 (dated 25- Jan-2018) is attached to the front of this protocol. 
  
 Clinical Study Protocol [ZIP_CODE] Page 53 of 55  
Version 3.0 / 15 -Feb-2018  
  
 
Reference Number: BHC- RD-OI-107 
Supplement: Version 5  16. Appendices  
 
16.1 Study Flow Chart 
Table 3: Study schema  
 
Protocol Activities  Screening Visit         
(within 28 days prior 
to oral surgery ) Dosing 
Period  
Inpatient  End of 
Trial Call  
(2-5 days 
after 
discharge)  Day 1 Day 2 
Written Informed Consent  x    
Inclusion/Exclusion Reviewed  x x   
Medical/Medication History  x x   
Physical and Oral Examination  x    
Vital Signsa x x x  
Urine  for Drug Screen and Cotinine  test x x   
Breath alcohol test  x x   
Dental x -ray examination  x    
Urine Pregnancy Test (if applicable)  x x   
Admission to Unit   x   
Oral surgery ( between 0 630 h and 1000 h (+/ - 30 minutes)   x   
Randomization Number Assigned   x   
Investigational Product Administration                        x   
Categorical  Pain Rating  Scale b    x   
Pain Intensity Numerical Rating Scale  (NRS)  c       x x  
Categorical Pain Relief Rating Scale c  x x  
Starting pain is at least ½ gonec  x x  
Global Assessment of Pain Relief  d   x  
Concomitant Medications   x x x 
Adverse Events Assessed  x x x x 
Discharge from Unit morning of Day 2    x  
a vital signs ( blood pressure, pulse rate, and respi[INVESTIGATOR_366288] 5 minutes).  On Day 1, vital signs are due post -surgery 
and [ADDRESS_457955] -dose.  
b to be completed prior to dosing  
c Pain Intensity NRS to be completed at baseline (predose),  and Pain Intensity NRS and Categorical Pain Relief will be assessed  0.5, 
1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, 16, 18, 20, 22 and 24 hours postdose.  I f rescue occurs, scales /question s (except pain ½ gone)  
will be completed immediately each time rescue medication is taken  
 d assessment will be completed immediately  before first rescue medication is taken or at [ADDRESS_457956]-dose  
 
 Clinical Study Protocol [ZIP_CODE] Page 54 of 55  
Version 3.0 / 15 -Feb-2018  
  
 
Reference Number: BHC- RD-OI-107 
Supplement: Version 5  16.2 Subjective Assessments 
 
Categorical Pain Intensity Scale ( predose) 
 
Finish the statement: “My pain at this time is” by [CONTACT_61951]. 
 
⁭ No Pain (0) 
⁭ Mild Pain (1) ⁭ Moderate Pain (2)  
⁭ Severe Pain (3) 
  
Numerical Rating Scale  (predose and post -dose) 
 
Circle a number to indicate level of pain (from 0 to 10) below to indicate the severity of the 
pain you are experiencing  at this time . 
 
[ADDRESS_457957] 
possible 
pain 
  
 
Categorical  Pain Relief Rating Scale (post-dose) 
 
Finish the statement: “ My relief from my starting pain is”” by [CONTACT_366327].  
 ☐ No Relief (0)  
☐  A Little Relief (1)  
☐ Some Relief (2)  
☐ A Lot of Relief (3)  
☐ Complete Relief (4)  
 
 
 
  
 Clinical Study Protocol [ZIP_CODE] Page 55 of 55  
Version 3.0 / 15 -Feb-2018  
  
 
Reference Number: BHC- RD-OI-107 
Supplement: Version [ADDRESS_457958] Pain Relief (post -dose) 
 
Finish the statement: “Is your starting pain at least ½ gone?” by [CONTACT_366327]. 
 
 ☐ No (0) 
 ☐ Yes (1)  
 
 
 
Global Assessment of Pain (post-dose) 
How would you rate the study medication you received as a pain -reliever?  
 
☐ Poor (0) 
☐ Fair (1)  
☐ Good (2) ☐ Very Good (3) ☐ Excellent (4)  
 
 
 
 